PrCr Preeclampsia Test (P/C)- MOQ is 500
-
The Protein to Creatinine (PrCr or P/C) test is a newer and more efficient way to screen for preeclampsia. This method assesses the ratio of protein to creatinine in the urine and is predictive of proteinuria >1.
- Faster way to assess the likelihood of preeclampsia
- Decreases delays in diagnosis and initiation of treatment
- Not yet for sale in the USA
- MOQ is 500
THE PROBLEM
Preeclampsia, a hypertensive disorder of pregnancy, is one of the leading causes of maternal and perinatal mortality and morbidity around the world. Characterized primarily by a new episode of hypertension during pregnancy, the disorder can also have a wide range of other symptoms, including proteinuria, a condition in which protein is present in higher levels in women with preeclampsia. Proteinuria can be measured alone in a 24-hour urine sample, but it can be time consuming and impractical in settings with large numbers of patients or patients coming from far away and needing to return home. In the absence of efficient testing, it can be difficult to diagnose and begin treating cases of preeclampsia.
THE SOLUTION
This test, called the 'spot-check', is a faster way to assess likelihood of preeclampsia and to identify women who will need monitoring and follow-up. A study in Turkey showed that "the urine spot P/C ratio above 0.9 mg/mg strongly predicts significant proteinuria of more than 1 gram.” In this published 2015 study, it is recommended that the Protein to Creatinine (P/C) ratio test be used to assess poor clinical status in order to prevent any delay in the implementation of treatment. Early diagnosis and treatment of preeclampsia can mitigate or halt potential morbidities or mortality.
Where is the price?
Pricing is based on shipping location and the number of units ordered. To request a price, please use the Request a Quote button below. A sales representative will respond to you quickly.
The Protein to Creatinine (PrCr or P/C) test is a newer and more efficient way to screen for preeclampsia. This method assesses the ratio of protein to creatinine in the urine and is predictive of proteinuria >1.
- Faster way to assess the likelihood of preeclampsia
- Decreases delays in diagnosis and initiation of treatment
- Not yet for sale in the USA
- MOQ is 500
THE PROBLEM
Preeclampsia, a hypertensive disorder of pregnancy, is one of the leading causes of maternal and perinatal mortality and morbidity around the world. Characterized primarily by a new episode of hypertension during pregnancy, the disorder can also have a wide range of other symptoms, including proteinuria, a condition in which protein is present in higher levels in women with preeclampsia. Proteinuria can be measured alone in a 24-hour urine sample, but it can be time consuming and impractical in settings with large numbers of patients or patients coming from far away and needing to return home. In the absence of efficient testing, it can be difficult to diagnose and begin treating cases of preeclampsia.
THE SOLUTION
This test, called the 'spot-check', is a faster way to assess likelihood of preeclampsia and to identify women who will need monitoring and follow-up. A study in Turkey showed that "the urine spot P/C ratio above 0.9 mg/mg strongly predicts significant proteinuria of more than 1 gram.” In this published 2015 study, it is recommended that the Protein to Creatinine (P/C) ratio test be used to assess poor clinical status in order to prevent any delay in the implementation of treatment. Early diagnosis and treatment of preeclampsia can mitigate or halt potential morbidities or mortality.